Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Niagen Bioscience (NAGE) over the last 11 years, with Q3 2025 value amounting to -$12000.0.

  • Niagen Bioscience's Asset Writedowns and Impairment fell 20000.0% to -$12000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 343717.95%. This contributed to the annual value of -$1.3 million for FY2024, which is 23485.48% down from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Asset Writedowns and Impairment is -$12000.0, which was down 20000.0% from $89000.0 recorded in Q2 2025.
  • Niagen Bioscience's 5-year Asset Writedowns and Impairment high stood at $400000.0 for Q2 2023, and its period low was -$1.4 million during Q4 2024.
  • Moreover, its 5-year median value for Asset Writedowns and Impairment was $14000.0 (2021), whereas its average is -$78947.4.
  • Per our database at Business Quant, Niagen Bioscience's Asset Writedowns and Impairment soared by 810000.0% in 2023 and then plummeted by 725263.16% in 2024.
  • Niagen Bioscience's Asset Writedowns and Impairment (Quarter) stood at $198000.0 in 2021, then plummeted by 82.32% to $35000.0 in 2022, then crashed by 45.71% to $19000.0 in 2023, then tumbled by 7252.63% to -$1.4 million in 2024, then surged by 99.12% to -$12000.0 in 2025.
  • Its Asset Writedowns and Impairment was -$12000.0 in Q3 2025, compared to $89000.0 in Q2 2025 and -$1.3 million in Q1 2025.